Decision Diagnostics Corp (DECN)

[Leirum]

Those who question the legitimacy of DECN may do so for their own reasons, but then it is not of importance, as J&J put the stamp of IMPORTANCE to the case and believe me , this is what counts at least for me as a shareholder .

The best reference about the quality of the Genstrip50 product (FDA approved) and the market potential comes from J&J or Lifescan. Who am I , to question this Multi-Billion Dollar company? Who am I, to challenge the statements from J&J’s lawyers, that if DECN would get away with it, they would be a serious competition to their market share of roughly $ 2,5 billion and who am I, to question even those legal minds, who covered this patent-infringement case in their Intellectual Property magazine.

http://www.sughrue.com/files/Publication/e2102668-3eea-4779-a633-7f1e6fb30230/Presentation/PublicationAttachment/8c039f86-839c-40f0-a1ef-80c0f7be1b16/90003000SuanPanMay2014.pdf

DECN must have done something right I guess, otherwise neither nor would have paid attention to it. As a matter of fact, DECN wrote Court-History.

“The Federal Circuit’s decision
in Lifescan Scotland, Ltd v
Shasta Tech, LLC summarises
Supreme Court precedent related
to exhaustion of both apparatus
patents and method patents.”


Since all started early 2013, DECN did not only attract the legal minds, they attracted as well some from the press who tried at that time – before the rulings were made in favor of DECN - to get a clearer picture of the consequences if and when DECN should survive this battle.

http://www.forbes.com/sites/genemarcial/2013/03/11/jj-faces-potentially-disrupting-competition-in-its-lucrative-glucose-monitoring-business-from-tiny-diagnostics-outfit/

http://www.forbes.com/sites/genemarcial/2013/09/11/jj-seeks-court-aid-to-protect-its-glucose-monitoring-test/

http://www.biomedreports.com/20131022158602/decn-set-to-climb-as-genstrip-enters-blood-glucose-monitoring-market-with-first-shipments.html

Of course as a consequence DECN became a litigation stock. How much will be paid and if it is amount x what would it mean for the stock and more. I have no idea, how much at the end will be in the account of DECN, but it will be certainly enough to emerge as a small company, debt-free and enough cash to fund the future. And as all who read the reports from the leading Wallstreet houses may know, the future for the industry to gather momentum and potential is in Asia and I guess, DECN to protect itself from unexpected challenges in the home-market and as experienced from the past-event and not to be hindered again to execute in this multi-billion dollar market could already have a strategy how to get this done. Welcome to Asia.

Just from a statistic point of view:

WHO Western Pacific Region calculates for the next 15 years a total of 370 Mio people with diabetes.

From this:

The Asian Pacific Rim - 75 Mio

The South-East Asia Region 120 Mio

In total more the 50 % in Asia.

You do not need to be smart to figure out where the biggest market potential outside of the USA is found and you do not need to be smart to figure out, where the biggest distributors have their jurisdiction.

Of course, DECN like any other company made it’s mistakes as a public company, but then it is not unique and even happens to the biggies. This from my point of view, although took longer than I thought, will soon be settled as well.

So actually we can look forward on 3 things:
- Some kind of settlement with J&J
- All filings out
- Presentation of the new DECN strategy with the hope that ASIA is fully covered.

At the latest then, DECN will be traded like any other stock: As a fully reporting company, with some cash in the bank and on the pad to generate substantial revenues.